The identification of new research initiatives, the creation of innovative and unique research projects and the nurturing of new investigators and coordinators are the cornerstones of the Parkinson Study Group's collaborative efforts and are essential to our goal of advancing knowledge.

The Scientific Review Committee (SRC) will review all research proposals coming to the PSG. A complete list of the SRC current committee members can be found on the PSG Overview web page.

The documents below establish the procedures and assist with the planning for new study proposals to be evaluated, reviewed and considered for approval as formal Parkinson Study Group projects.

The PSG encourages projects which include retrospective analyses of PSG clinical trial databases. We have compiled a list of all the PSG databases that are available. Please see PSG Database Inventory for detailed information.

More specific study-related information can be found on the Database Inventory Assessments Spreadsheet.

To review examples of projects that retrospectively analyzed PSG clinical trial databases, please see the following publications:

• Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease.
  
• Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients.
  
• Freezing of gait in PD: Prospective assessment in the DATATOP cohort.
  
• Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson’s disease.
  
• Test-retest reliability of the Unified Parkinson’s Disease Rating Scale in patients with early Parkinson’s disease: Results from a multicenter clinical trial.
  
• Quality of life in early Parkinson’s disease: Impact of dyskinesias and motor fluctuations.
  
• Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort.

Below is an example of a successful mentored research award proposal:

• PSG Research/Mentorship Grant Award: “A family study of LRRK2 mutations: Establishing evaluation and screening methods” by Connie Marras, MD, Morton and Gloria Shulman, Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario.
  

PSG OVERVIEW | PARKINSON'S DISEASE OVERVIEW
WHAT IS A CLINICAL TRIAL

CLINICAL TRIALS IN PROGRESS

COMPLETED CLINICAL TRIALS | PSG / MDS SYMPOSIA | PUBLICATIONS / ABSTRACTS

CONTRIBUTIONS | OTHER USEFUL LINKS